BIOMARKER:

TNFRSF8 positive

Entrez ID:

Related biomarkers:

‹

›

TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	brentuximab vedotin Sensitive: A1 - Approval	brentuximab vedotin Sensitive: A1 - Approval
TNFRSF8 positive TNFRSF8 positive	Cutaneous T-cell Lymphoma Cutaneous T-cell Lymphoma	TNFRSF8 positive TNFRSF8 positive	Cutaneous T-cell Lymphoma Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval	brentuximab vedotin Sensitive: A1 - Approval
TNFRSF8 positive TNFRSF8 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	TNFRSF8 positive TNFRSF8 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline	brentuximab vedotin Sensitive: A2 - Guideline
TNFRSF8 positive TNFRSF8 positive	Non-Hodgkin’s Lymphoma NHL	TNFRSF8 positive TNFRSF8 positive	Non-Hodgkin’s Lymphoma NHL	CD30.CAR-T cell therapy Sensitive: C2 – Inclusion Criteria	CD30.CAR-T cell therapy Sensitive: C2 – Inclusion Criteria
TNFRSF8 positive TNFRSF8 positive	Lymphoma Lymphoma	TNFRSF8 positive TNFRSF8 positive	Lymphoma Lymphoma	AFM13 + NK cell stimulant Sensitive: C2 – Inclusion Criteria	AFM13 + NK cell stimulant Sensitive: C2 – Inclusion Criteria
TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	CD30.CAR-T cell therapy Sensitive: C3 – Early Trials	CD30.CAR-T cell therapy Sensitive: C3 – Early Trials
TNFRSF8 positive TNFRSF8 positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	TNFRSF8 positive TNFRSF8 positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	BV-ICE Sensitive: C3 – Early Trials	BV-ICE Sensitive: C3 – Early Trials